Abpro Bio Balance Sheet Health
Financial Health criteria checks 5/6
Abpro Bio has a total shareholder equity of ₩122.7B and total debt of ₩18.0B, which brings its debt-to-equity ratio to 14.7%. Its total assets and total liabilities are ₩153.3B and ₩30.7B respectively.
Key information
14.7%
Debt to equity ratio
₩18.01b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩7.88b |
| Equity | ₩122.67b |
| Total liabilities | ₩30.68b |
| Total assets | ₩153.35b |
Recent financial health updates
We Think Abpro Bio (KOSDAQ:195990) Has A Fair Chunk Of Debt
Oct 21
Is Abpro Bio (KOSDAQ:195990) Using Debt In A Risky Way?
Apr 05Recent updates
We Think Abpro Bio (KOSDAQ:195990) Has A Fair Chunk Of Debt
Oct 21Getting In Cheap On Abpro Bio Co., Ltd. (KOSDAQ:195990) Is Unlikely
Jul 12Revenues Not Telling The Story For Abpro Bio Co., Ltd. (KOSDAQ:195990)
Mar 14Is Abpro Bio (KOSDAQ:195990) Using Debt In A Risky Way?
Apr 05Abpro Bio (KOSDAQ:195990) Shareholders Booked A 92% Gain In The Last Year
Feb 02Financial Position Analysis
Short Term Liabilities: A195990's short term assets (₩48.8B) exceed its short term liabilities (₩24.7B).
Long Term Liabilities: A195990's short term assets (₩48.8B) exceed its long term liabilities (₩6.0B).
Debt to Equity History and Analysis
Debt Level: A195990's net debt to equity ratio (8.3%) is considered satisfactory.
Reducing Debt: A195990's debt to equity ratio has reduced from 58.5% to 14.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A195990 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: A195990 has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 15.3% each year.